Allogeneic stem cell transplantation for trisomy 8-positive myelodysplastic syndrome or myelodysplastic/myeloproliferative disease with refractory Behçet's disease: Case report and the review of literature.
Behçet’s disease
Trisomy 8
myelodysplastic syndrome
stem cell transplantation
Journal
Modern rheumatology case reports
ISSN: 2472-5625
Titre abrégé: Mod Rheumatol Case Rep
Pays: England
ID NLM: 101761026
Informations de publication
Date de publication:
24 06 2022
24 06 2022
Historique:
received:
17
01
2022
revised:
12
02
2022
accepted:
25
03
2022
pubmed:
3
4
2022
medline:
28
6
2022
entrez:
2
4
2022
Statut:
ppublish
Résumé
We had two cases of trisomy 8-positive myelodysplastic syndrome (MDS) with incomplete Behçet's disease (BD) in which the remissions of both diseases were maintained by allogeneic stem cell transplantation (allo-SCT). Among MDS with BD patients, sometimes it is difficult to control the symptoms of BD with standard therapies such as corticosteroids and tumor necrosis factor (TNF) inhibitors. Although there should be careful consideration regarding indications for transplantation, our two cases, in which refractory BD was completely controlled by allo-SCT, suggest that allo-SCT can be one of the treatment options for higher-risk MDS with BD patients.
Identifiants
pubmed: 35365826
pii: 6562592
doi: 10.1093/mrcr/rxac032
doi:
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
273-277Informations de copyright
© Japan College of Rheumatology 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.